CA3172751A1 - Methods of treating copper metabolism-associated diseases or disorders - Google Patents
Methods of treating copper metabolism-associated diseases or disorders Download PDFInfo
- Publication number
- CA3172751A1 CA3172751A1 CA3172751A CA3172751A CA3172751A1 CA 3172751 A1 CA3172751 A1 CA 3172751A1 CA 3172751 A CA3172751 A CA 3172751A CA 3172751 A CA3172751 A CA 3172751A CA 3172751 A1 CA3172751 A1 CA 3172751A1
- Authority
- CA
- Canada
- Prior art keywords
- subject
- copper
- biological sample
- bis
- ratio
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6827—Total protein determination, e.g. albumin in urine
- G01N33/683—Total protein determination, e.g. albumin in urine involving metal ions
- G01N33/6833—Copper, e.g. Folin-, Lowry-, biuret methods
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Computational Biology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063113516P | 2020-11-13 | 2020-11-13 | |
| US63/113,516 | 2020-11-13 | ||
| US202163242722P | 2021-09-10 | 2021-09-10 | |
| US63/242,722 | 2021-09-10 | ||
| PCT/US2021/059239 WO2022104135A1 (en) | 2020-11-13 | 2021-11-12 | Methods of treating copper metabolism-associated diseases or disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3172751A1 true CA3172751A1 (en) | 2022-05-19 |
Family
ID=78844761
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3172751A Pending CA3172751A1 (en) | 2020-11-13 | 2021-11-12 | Methods of treating copper metabolism-associated diseases or disorders |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20230414654A1 (https=) |
| EP (1) | EP4243806A1 (https=) |
| JP (1) | JP2023549814A (https=) |
| CA (1) | CA3172751A1 (https=) |
| WO (1) | WO2022104135A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023023199A1 (en) * | 2021-08-17 | 2023-02-23 | Alexion Pharmaceuticals, Inc. | Methods of treating copper metabolism-associated diseases or disorders |
| WO2023038909A1 (en) * | 2021-09-07 | 2023-03-16 | Alexion Pharmaceuticals, Inc. | Methods of treating copper metabolism-associated diseases or disorders |
| WO2024162974A1 (en) * | 2023-01-30 | 2024-08-08 | Alexion Pharmaceuticals, Inc. | Tetrathiomolybdic acid for use in treating copper metabolism-associated diseases or disorders (wilson disease) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020006284A (es) * | 2017-12-04 | 2021-04-12 | Alexion Pharma Int Operations Unlimited Company | Tetratiomolibdato de bis-colina para tratar la enfermedad de wilson. |
| US20220334135A1 (en) | 2019-09-12 | 2022-10-20 | Alexion Pharmaceuticals, Inc. | Methods of measuring copper concentration in biological samples |
-
2021
- 2021-11-12 EP EP21824150.3A patent/EP4243806A1/en active Pending
- 2021-11-12 CA CA3172751A patent/CA3172751A1/en active Pending
- 2021-11-12 JP JP2023528431A patent/JP2023549814A/ja active Pending
- 2021-11-12 WO PCT/US2021/059239 patent/WO2022104135A1/en not_active Ceased
- 2021-11-12 US US18/036,617 patent/US20230414654A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4243806A1 (en) | 2023-09-20 |
| JP2023549814A (ja) | 2023-11-29 |
| US20230414654A1 (en) | 2023-12-28 |
| WO2022104135A1 (en) | 2022-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3172751A1 (en) | Methods of treating copper metabolism-associated diseases or disorders | |
| US20210116467A1 (en) | Diabetes-related biomarkers and treatment of diabetes-related conditions | |
| McKay et al. | Endocrine and metabolic pathways linked to keratoconus: implications for the role of hormones in the stromal microenvironment | |
| Chen et al. | Integrated tear proteome and metabolome reveal panels of inflammatory-related molecules via key regulatory pathways in dry eye syndrome | |
| US20250051461A1 (en) | Methods for the treatment of thyroid eye disease | |
| CN107121555B (zh) | 评估肾结构改变和结果 | |
| US20170003291A1 (en) | Methods for detecting, diagnosing and treating endometrial cancer | |
| Zheng et al. | Increased plasma DPP4 activity predicts new-onset hypertension in Chinese over a 4-year period: possible associations with inflammation and oxidative stress | |
| Mu et al. | Comparison of two regimens for patients with thyroid-associated ophthalmopathy receiving intravenous methyl prednisolone: a single center prospective randomized trial | |
| Mandal et al. | Association of ABO blood groups with type-2 diabetes mellitus and its complications | |
| ES2552816T3 (es) | Procedimiento para identificar pacientes con trastornos cognitivos leves que necesitan terapia y tratamiento de pacientes de este tipo | |
| KR20110134907A (ko) | 근변성 질환의 검출 방법 및 치료 효과 판정 방법 | |
| JP2020525416A (ja) | 眼表面障害の治療及び診断 | |
| JP2024532131A (ja) | 銅代謝関連疾患又は障害を治療する方法 | |
| US20250249011A1 (en) | Methods for treating a fatty liver disease | |
| Shankar et al. | Positive association between plasma homocysteine level and chronic kidney disease | |
| Yang et al. | Fasting plasma glucose levels predict steroid-induced abnormal glucose metabolism in patients with non-diabetic chronic kidney disease: a prospective cohort study | |
| CN116685334A (zh) | 治疗铜代谢相关疾病或障碍的方法 | |
| Eisendle et al. | Pruritus of unknown origin and elevated total serum bile acid levels in patients without clinically apparent liver disease | |
| Meng et al. | Interaction analysis of systolic blood pressure and glycosylated hemoglobin in diabetic retinopathy: A Chinese sample | |
| Wang et al. | Plasma metabolomic profiling of diabetic macular edema | |
| Gowtham et al. | Profiling lipidomic variations in primary open-angle and angle-closure glaucoma patients | |
| Tripathee et al. | PS-C22-2: Understanding Clinical Effectiveness of Telmisartan as Monotherapy for Hypertension management in Nepal | |
| US20200191802A1 (en) | Methods for diagnosing or predicting chronic bronchitis | |
| JP5069804B2 (ja) | 筋萎縮性側索硬化症（ａｌｓ）の患者の進行度を判定し進行のモニターを行う方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220921 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241108 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241108 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241108 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250707 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251023 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251023 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20251107 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260102 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260102 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260102 |